Mario Venditti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8444514/publications.pdf

Version: 2024-02-01

201 papers

8,534 citations

41258 49 h-index 83 g-index

205 all docs

205
docs citations

times ranked

205

10151 citing authors

#	Article	IF	CITATIONS
1	Effect of Heart Rate Control With Esmolol on Hemodynamic and Clinical Outcomes in Patients With Septic Shock. JAMA - Journal of the American Medical Association, 2013, 310, 1683.	3.8	542
2	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	4.6	367
3	Invasive Infections Caused by Trichosporon Species and Geotrichum capitatum in Patients with Hematological Malignancies: a Retrospective Multicenter Study from Italy and Review of the Literature. Journal of Clinical Microbiology, 2005, 43, 1818-1828.	1.8	347
4	Cirrhotic Patients Are at Risk for Health Care–Associated Bacterial Infections. Clinical Gastroenterology and Hepatology, 2010, 8, 979-985.e1.	2.4	274
5	Outcomes of Patients Hospitalized With Community-Acquired, Health Care–Associated, and Hospital-Acquired Pneumonia. Annals of Internal Medicine, 2009, 150, 19.	2.0	267
6	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by⟨i⟩Klebsiella pneumoniae⟨ i⟩Carbapenemase–producing⟨i⟩K. pneumoniae⟨ i⟩. Clinical Infectious Diseases, 2019, 68, 355-364.	2.9	265
7	Klebsiella pneumoniae ST258 Producing KPC-3 Identified in Italy Carries Novel Plasmids and OmpK36/OmpK35 Porin Variants. Antimicrobial Agents and Chemotherapy, 2012, 56, 2143-2145.	1.4	169
8	Cardiovascular Complications and Short-term Mortality Risk in Community-Acquired Pneumonia. Clinical Infectious Diseases, 2017, 64, 1486-1493.	2.9	162
9	Bacteremia Due to Stenotrophomonas maltophilia in Patients with Hematologic Malignancies. Clinical Infectious Diseases, 2000, 31, 705-711.	2.9	153
10	Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Medicine, 2009, 35, 55-62.	3.9	148
11	A Multinational, Preregistered Cohort Study of \hat{l}^2 -Lactam/ \hat{l}^2 -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- \hat{l}^2 -Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	1.4	137
12	Relationship between biofilm formation, the enterococcal surface protein (Esp) and gelatinase in clinical isolates of Enterococcus faecalisand Enterococcus faecium. FEMS Microbiology Letters, 2006, 256, 145-150.	0.7	133
13	Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study. Clinical Infectious Diseases, 2021, 73, 1664-1676.	2.9	130
14	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Critical Care, 2019, 23, 219.	2.5	123
15	Considerations for Higher Doses of Daptomycin in Critically Ill Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia. Clinical Infectious Diseases, 2013, 57, 1568-1576.	2.9	118
16	Nox2 activation in Covid-19. Redox Biology, 2020, 36, 101655.	3.9	114
17	Candida Infective Endocarditis. Medicine (United States), 2009, 88, 160-168.	0.4	113
18	Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase–producing K.Âpneumoniae. Clinical Microbiology and Infection, 2016, 22, 444-450.	2.8	112

#	Article	IF	CITATIONS
19	An Ertapenem-Resistant Extended-Spectrum- \hat{l}^2 -Lactamase-Producing <i>Klebsiella pneumoniae</i> Carries a Novel OmpK36 Porin Variant. Antimicrobial Agents and Chemotherapy, 2010, 54, 4178-4184.	1.4	110
20	Microvascular Effects of Heart Rate Control With Esmolol in Patients With Septic Shock. Critical Care Medicine, 2013, 41, 2162-2168.	0.4	98
21	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	1.4	89
22	The chronic use of betaâ€blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver International, 2015, 35, 362-369.	1.9	88
23	Successful Ertapenem-Doripenem Combination Treatment of Bacteremic Ventilator-Associated Pneumonia Due to Colistin-Resistant KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2013, 57, 2900-2901.	1.4	86
24	Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. World Journal of Gastroenterology, 2008, 14, 2757.	1.4	82
25	Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. Journal of Chemotherapy, 2017, 29, 197-214.	0.7	81
26	Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit. Infection, 2022, 50, 83-92.	2.3	81
27	Invasive aspergillosis in patients with liver disease. Medical Mycology, 2011, 49, 406-413.	0.3	78
28	The Spread of Multi Drug Resistant Infections Is Leading to an Increase in the Empirical Antibiotic Treatment Failure in Cirrhosis: A Prospective Survey. PLoS ONE, 2015, 10, e0127448.	1.1	78
29	Lower Mortality Rate in Elderly Patients With Communityâ€Onset Pneumonia on Treatment With Aspirin. Journal of the American Heart Association, 2015, 4, e001595.	1.6	78
30	Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment. Intensive Care Medicine, 2009, 35, 206-214.	3.9	75
31	Increased risk of cognitive impairment in cirrhotic patients with bacterial infections. Journal of Hepatology, 2013, 59, 243-250.	1.8	72
32	Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Critical Care, 2013, 17, R174.	2.5	72
33	Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. Journal of Infection, 2019, 79, 130-138.	1.7	67
34	An empirical broad spectrum antibiotic therapy in healthâ€care–associated infections improves survival in patients with cirrhosis: A randomized trial. Hepatology, 2016, 63, 1632-1639.	3.6	66
35	Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?. Journal of Infection and Chemotherapy, 2013, 19, 732-739.	0.8	65
36	Clonal Multidrug-Resistant <i>Corynebacterium striatum</i> Strains, Italy. Emerging Infectious Diseases, 2009, 15, 75-78.	2.0	64

#	Article	IF	CITATIONS
37	Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. Circulation Research, 2020, 127, 400-401.	2.0	60
38	Evidence-Based Criteria for the Choice and the Clinical use of the Most Appropriate Lock Solutions for Central Venous Catheters (Excluding Dialysis Catheters): A GAVeCeLT Consensus. Journal of Vascular Access, 2016, 17, 453-464.	0.5	59
39	Performance of PSI, CURB-65, and SCAP scores in predicting the outcome of patients with community-acquired and healthcare-associated pneumonia. Internal and Emergency Medicine, 2011, 6, 431-436.	1.0	58
40	Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case–control study. Infection, 2013, 41, 61-67.	2.3	57
41	Risk Factors and Outcomes of Endocarditis Due to Non-HACEK Gram-Negative Bacilli: Data from the Prospective Multicenter Italian Endocarditis Study Cohort. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	56
42	Healthcare-associated pneumonia: Diagnostic criteria and distinction from community-acquired pneumonia. International Journal of Infectious Diseases, 2011, 15, e545-e550.	1.5	55
43	Clinical features and outcome of patients with descending necrotizing mediastinitis: prospective analysis of 34 cases. Infection, 2016, 44, 77-84.	2.3	55
44	Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study. Frontiers in Nutrition, 2020, 7, 613928.	1.6	55
45	Individualizing Risk of Multidrug-Resistant Pathogens in Community-Onset Pneumonia. PLoS ONE, 2015, 10, e0119528.	1.1	55
46	Infections with VIM-1 Metallo- \hat{l}^2 -Lactamase-Producing <i>Enterobacter cloacae</i> and Their Correlation with Clinical Outcome. Journal of Clinical Microbiology, 2009, 47, 3514-3519.	1.8	54
47	Risk factors and clinical significance of ertapenem-resistant Klebsiella pneumoniae in hospitalised patients. Journal of Hospital Infection, 2011, 78, 54-58.	1.4	54
48	Surveillance and management of multidrug-resistant microorganisms. Expert Review of Anti-Infective Therapy, 2011, 9, 653-679.	2.0	54
49	Expanded CURB-65: a new score system predicts severity of community-acquired pneumonia with superior efficiency. Scientific Reports, 2016, 6, 22911.	1.6	54
50	Valvular perforation in left-sided infective endocarditis: A prospective echocardiographic evaluation and clinical outcome. American Heart Journal, 1997, 134, 656-664.	1,2	53
51	Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections. International Journal of Infectious Diseases, 2010, 14, S67-S77.	1.5	53
52	Hospital-acquired infection surveillance in a neonatal intensive care unit. American Journal of Infection Control, 2009, 37, 201-203.	1.1	52
53	De-escalation and discontinuation strategies in high-risk neutropenic patients: an interrupted time series analyses of antimicrobial consumption and impact on outcome. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1931-1940.	1.3	52
54	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>Escherichia coli</i> and ESBL-Producing <i>Klebsiella pneumoniae</i> Infection Control and Hospital Epidemiology, 2018, 39, 660-667.	1.0	49

#	Article	IF	CITATIONS
55	Comparison of Septic Shock Due to Multidrug-Resistant Acinetobacter baumannii or Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Intensive Care Unit Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	47
56	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- $\langle b \rangle \hat{l}^2 \langle b \rangle$ -lactamase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw513.	1.3	46
57	Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection. Antimicrobial Agents and Chemotherapy, 2016, 60, 252-257.	1.4	45
58	A low muscle mass increases mortality in compensated cirrhotic patients with sepsis. Liver International, 2018, 38, 851-857.	1.9	45
59	Antibiotic resistance and genotypic characterization by PFGE of clinical and environmental isolates of enterococci. FEMS Microbiology Letters, 2001, 201, 205-211.	0.7	43
60	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	2.9	43
61	Characterization of a Variant of the SCCmecElement in a Bloodstream Isolate ofStaphylococcus intermedius. Microbial Drug Resistance, 2007, 13, 7-10.	0.9	42
62	Methicillin-resistant <i>Staphylococcus aureus</i> Necrotizing Pneumonia. Emerging Infectious Diseases, 2005, 11, 1647-1648.	2.0	41
63	Changing Italian nosocomial-community trends and heteroresistance in Staphylococcus aureus from bacteremia and endocarditis. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 739-745.	1.3	41
64	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	1.3	41
65	Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii. Journal of Global Antimicrobial Resistance, 2020, 23, 292-296.	0.9	41
66	Is teicoplanin a complementary treatment option for COVID-19? The question remains. International Journal of Antimicrobial Agents, 2020, 56, 106029.	1.1	41
67	Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2021, 65, e0057421.	1.4	41
68	Novel Insights and Features of the NDM-5-Producing Escherichia coli Sequence Type 167 High-Risk Clone. MSphere, 2020, 5, .	1.3	39
69	Staphylococcus aureus bacteremia in patients with hematologic malignancies: a retrospective case-control study. Haematologica, 2003, 88, 923-30.	1.7	39
70	Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl. Pediatric Diabetes, 2009, 10, 289-293.	1.2	36
71	Retrospective case–control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy. International Journal of Antimicrobial Agents, 2012, 39, 64-68.	1.1	36
72	Simplified Equations Using Two Concentrations To Calculate Area under the Curve for Antimicrobials with Concentration-Dependent Pharmacodynamics: Daptomycin as a Motivating Example. Antimicrobial Agents and Chemotherapy, 2014, 58, 3162-3167.	1.4	36

#	Article	IF	Citations
73	Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum \hat{l}^2 -lactamase-producing Enterobacteriaceae. International Journal of Antimicrobial Agents, 2018, 52, 577-585.	1.1	36
74	Albumin Supplementation Dampens Hypercoagulability in COVID-19: A Preliminary Report. Thrombosis and Haemostasis, 2021, 121, 102-105.	1.8	36
75	Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). International Journal	1.1	36
76	Assessment of risk factors for candidemia in non-neutropenic patients hospitalized in Internal Medicine wards: A multicenter study. European Journal of Internal Medicine, 2017, 41, 33-38.	1.0	35
77	Serious infections due to methicillin-resistant Staphylococcus aureus: An evolving challenge for physicians. European Journal of Internal Medicine, 2009, 20, 343-347.	1.0	34
78	Staphylococcus haemolyticus endocarditis: clinical and microbiologic analysis of 4 cases. Diagnostic Microbiology and Infectious Disease, 2007, 57, 325-331.	0.8	33
79	Optimizing antibiotic therapy of bacteremia and endocarditis due to staphylococci and enterococci: New insights and evidence from the literature. Journal of Infection and Chemotherapy, 2015, 21, 330-339.	0.8	33
80	Low-Grade Endotoxemia and Thrombosis in COVID-19. Clinical and Translational Gastroenterology, 2021, 12, e00348.	1.3	32
81	Corticosteroid Use and Incident Myocardial Infarction in Adults Hospitalized for Community-acquired Pneumonia. Annals of the American Thoracic Society, 2019, 16, 91-98.	1.5	31
82	Linezolid-resistant staphylococcal bacteraemia: A multicentre case–case–control study in Italy. International Journal of Antimicrobial Agents, 2015, 45, 255-261.	1.1	30
83	Clinical significance of lymphocytopenia in patients hospitalized with pneumonia caused by influenza virus. Critical Care, 2019, 23, 330.	2.5	30
84	Candidemia Subsequent to Severe Infection Due to Clostridium difficile: Is There a Link?. Clinical Infectious Diseases, 2013, 57, 772-774.	2.9	29
85	Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection. Clinical Microbiology and Infection, 2015, 21, 493.e1-493.e4.	2.8	29
86	Use of colistin in adult patients: A cross-sectional study. Journal of Global Antimicrobial Resistance, 2020, 20, 43-49.	0.9	29
87	Clinical impact of broad-spectrum empirical antibiotic therapy in patients with healthcare-associated pneumonia: a multicenter interventional study. Internal and Emergency Medicine, 2012, 7, 523-531.	1.0	28
88	Predictors of mortality in nursing-home residents with pneumonia: a multicentre study. Clinical Microbiology and Infection, 2018, 24, 72-77.	2.8	28
89	<p>A case of persistent bacteraemia by Ralstonia mannitolilytica and Ralstonia pickettii in an intensive care unit</p> . Infection and Drug Resistance, 2019, Volume 12, 2391-2395.	1.1	27
90	Hospitalization for Pneumonia is Associated With Decreased 1-Year Survival in Patients With Type 2 Diabetes. Medicine (United States), 2016, 95, e2531.	0.4	25

#	Article	IF	Citations
91	Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For. Journal of Thoracic Oncology, 2021, 16, 546-571.	0.5	25
92	Surveillance and Infection Control in an Intensive Care Unit. Infection Control and Hospital Epidemiology, 2005, 26, 321-325.	1.0	24
93	Daptomycin plus trimethoprim/sulfamethoxazole combination therapy in post-neurosurgical meningitis caused by linezolid-resistant Staphylococcus epidermidis. Diagnostic Microbiology and Infectious Disease, 2013, 76, 99-102.	0.8	24
94	Biofilm-Related Infections in Gram-Positive Bacteria and the Potential Role of the Long-Acting Agent Dalbavancin. Frontiers in Microbiology, 2021, 12, 749685.	1.5	24
95	Clinical Aspects of Invasive Candidiasis. Drugs, 2009, 69, 39-43.	4.9	23
96	Presepsin as a potential marker for bacterial infection relapse in critical care patients. A preliminary study. Clinical Chemistry and Laboratory Medicine, 2014, 53, 567-73.	1.4	23
97	Identification and management of invasive mycoses in internal medicine: a road-map for physicians. Internal and Emergency Medicine, 2014, 9, 501-511.	1.0	23
98	<i>Candida</i> endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian Study of Endocarditis. Expert Review of Anti-Infective Therapy, 2017, 15, 807-818.	2.0	23
99	Teicoplanin use and emergence of Staphylococcus haemolyticus: is there a link?. Clinical Microbiology and Infection, 2006, 12, 96-97.	2.8	22
100	Outbreak of Acinetobacter baumannii Producing the Carbapenem-Hydrolyzing Oxacillinase OXA-58 in Rome, Italy. Microbial Drug Resistance, 2007, 13, 37-43.	0.9	22
101	Daptomycin serum levels in critical patients undergoing continuous renal replacement. Journal of Chemotherapy, 2012, 24, 253-256.	0.7	21
102	Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: A Case Report. Open Forum Infectious Diseases, 2019, 6, ofz427.	0.4	21
103	Worrisome Trend of New Multiple Mechanisms of Linezolid Resistance in Staphylococcal Clones Diffused in Italy. Journal of Clinical Microbiology, 2013, 51, 1256-1259.	1.8	20
104	Predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis: does galactomannan have a role?. Diagnostic Microbiology and Infectious Disease, 2014, 80, 83-86.	0.8	20
105	The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit. BMC Infectious Diseases, 2015, 15, 393.	1.3	20
106	The role of teicoplanin in the treatment of SARSâ€CoVâ€2 infection: A retrospective study in critically ill COVIDâ€19 patients (Teiâ€COVID study). Journal of Medical Virology, 2021, 93, 4319-4325.	2.5	20
107	Class I Integron-Borne (i>bla (i> < sub > VIM-1 < / sub > Carbapenemase in a Strain of (i> Enterobacter cloacae < / i> Responsible for a Case of Fatal Pneumonia. Microbial Drug Resistance, 2008, 14, 45-47.	0.9	18
108	Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: Analysis of a 14-Month Prospective Clinical Experience. Journal of Chemotherapy, 2011, 23, 290-294.	0.7	18

7

#	Article	IF	CITATIONS
109	Early, intermediate and late infectious complications after transcatheter or surgical aortic-valve replacement: a prospective cohort study. Clinical Microbiology and Infection, 2014, 20, 758-763.	2.8	18
110	Challenges in the Microbiological Diagnosis of Implant-Associated Infections: A Summary of the Current Knowledge. Frontiers in Microbiology, 2021, 12, 750460.	1.5	18
111	Comparison of Thrombotic Events and Mortality in Patients with Community-Acquired Pneumonia and COVID-19: A Multicenter Observational Study. Thrombosis and Haemostasis, 2022, 122, 257-266.	1.8	18
112	Clinical Impact of COVID-19 on Multi-Drug-Resistant Gram-Negative Bacilli Bloodstream Infections in an Intensive Care Unit Setting: Two Pandemics Compared. Antibiotics, 2022, 11, 926.	1.5	18
113	Intra-abdominal infections: model of antibiotic stewardship in an era with limited antimicrobial options. International Journal of Antimicrobial Agents, 2011, 38, 271-272.	1.1	17
114	Persistent Systemic Microbial Translocation, Inflammation, and Intestinal Damage During Clostridioides difficile Infection. Open Forum Infectious Diseases, 2020, 7, ofz507.	0.4	17
115	Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : a multicentre study. JAC-Antimicrobial Resistance, 2022, 4, dlac022.	0.9	17
116	Candidemia in Patients with Body Temperature Below $37\hat{A}^{\circ}\text{C}$ and Admitted to Internal Medicine Wards: Assessment of Risk Factors. American Journal of Medicine, 2016, 129, 1330.e1-1330.e6.	0.6	16
117	Septic shock from community-onset pneumonia: is there a role for aspirin plus macrolides combination?. Intensive Care Medicine, 2016, 42, 301-302.	3.9	16
118	Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing K. pneumoniae Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside. Antibiotics, 2021, 10, 781.	1.5	16
119	In vitro activity of daptomycin against methicillin- and multi-resistant Staphylococcus haemolyticus invasive isolates carrying different mec complexes. Diagnostic Microbiology and Infectious Disease, 2008, 61, 227-231.	0.8	15
120	Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes. Clinical Microbiology and Infection, 2019, 25, 474-480.	2.8	15
121	Prolonged bacteraemia caused by VIM-1 metallo- \hat{l}^2 -lactamase-producing Proteus mirabilis: first report from Italy. Clinical Microbiology and Infection, 2010, 16, 179-181.	2.8	14
122	Role of multidrug-resistant pathogens in health-care-associated pneumonia. Lancet Infectious Diseases, The, 2011, 11, 11-12.	4.6	14
123	Candidal thrombophlebitis of central veins: case report and review. Medical Mycology, 2012, 50, 299-304.	0.3	14
124	NEW INSIGHT ON EPIDEMIOLOGY AND MANAGEMENT OF BACTERIAL BLOODSTREAM INFECTION IN PATIENTS WITH HEMATOLOGICAL MALIGNACIES. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015044.	0.5	14
125	A challenging case of carbapenemase-producing Klebsiella pneumoniae septic thrombophlebitis and right mural endocarditis successfully treated with ceftazidime/avibactam. Infection, 2018, 46, 721-724.	2.3	14
126	Procalcitonin in the Assessment of Ventilator Associated Pneumonia: A Systematic Review. Advances in Experimental Medicine and Biology, 2020, 1323, 103-114.	0.8	14

#	Article	IF	CITATIONS
127	Are Follow-Up Blood Cultures Useful in the Antimicrobial Management of Gram Negative Bacteremia? A Reappraisal of Their Role Based on Current Knowledge. Antibiotics, 2020, 9, 895.	1.5	14
128	Rapidly Fatal Hemorrhagic Pneumonia and Group A <i>Streptococcus</i> Serotype M1. Emerging Infectious Diseases, 2013, 20, 98-101.	2.0	13
129	A cluster of fulminant Clostridium difficile colitis in an intensive care unit in Italy. Infection, 2014, 42, 585-589.	2.3	13
130	Voriconazole treatment of Candida tropicalis meningitis. Medicine (United States), 2016, 95, e4474.	0.4	13
131	Broadly reactive human CD4 $<$ sup $>+<$ /sup $>$ T cells against Enterobacteriaceae are found in the na \tilde{A} -ve repertoire and are clonally expanded in the memory repertoire. European Journal of Immunology, 2021, 51, 648-661.	1.6	13
132	Effect of N-Acetylcysteine Administration on 30-Day Mortality in Critically Ill Patients with Septic Shock Caused by Carbapenem-Resistant Klebsiella pneumoniae and Acinetobacter baumannii: A Retrospective Case-Control Study. Antibiotics, 2021, 10, 271.	1.5	13
133	Follow-up blood cultures in Gram-negative bacilli bacteremia: are they needed for critically ill patients?. Minerva Anestesiologica, 2020, 86, 498-506.	0.6	13
134	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infectious Diseases and Therapy, 2022, 11, 827-840.	1.8	13
135	Superinfections caused by carbapenem-resistant Enterobacterales in hospitalized patients with COVID-19: a multicentre observational study from Italy (CREVID Study). JAC-Antimicrobial Resistance, 2022, 4, .	0.9	13
136	Follow-up Blood Cultures: A 2.0 Diagnostic Tool in Patients With Gram-Negative Bacteremia and Septic Thrombophlebitis. Clinical Infectious Diseases, 2018, 66, 1154-1155.	2.9	12
137	Case report 5: Intensive care unit patient assessed using the Candida Score. Mycoses, 2010, 53, 12-13.	1.8	11
138	Impact of Initial Antifungal Therapy on the Outcome of Patients With Candidemia and Septic Shock Admitted to Medical Wards: A Propensity Score–Adjusted Analysis. Open Forum Infectious Diseases, 2019, 6, ofz251.	0.4	11
139	Superinfections in patients treated with Teicoplanin as antiâ€SARSâ€CoVâ€2 agent. European Journal of Clinical Investigation, 2021, 51, e13418.	1.7	11
140	The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. Expert Review of Anti-Infective Therapy, 2021, 19, 1125-1134.	2.0	11
141	Place in Therapy of the Newly Available Armamentarium for Multi-Drug-Resistant Gram-Negative Pathogens: Proposal of a Prescription Algorithm. Antibiotics, 2021, 10, 1475.	1.5	11
142	The ADA (Age-D-Dimer-Albumin) Score to Predict Thrombosis in SARS-CoV-2. Thrombosis and Haemostasis, 2022, 122, 1567-1572.	1.8	11
143	A plasma expander-related Pseudomonas aeruginosa outbreak. Scandinavian Journal of Infectious Diseases, 2006, 38, 1085-1088.	1.5	10
144	Occurrence of influenza A(H1N1)v infection and concomitant invasive pulmonary aspergillosis in a patient with chronic obstructive pulmonary disease. Mycoses, 2011, 54, 549-551.	1.8	10

#	Article	IF	CITATIONS
145	Prospective Study on Incidence, Risk Factors and Outcome of Recurrent Clostridioides difficile Infections. Journal of Clinical Medicine, 2021, 10, 1127.	1.0	10
146	Interplay between Klebsiella pneumoniae producing KPC-31 and KPC-3 under treatment with high dosage meropenem: a case report. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 495-500.	1.3	10
147	Reliability of white blood cell scan in the follow-up of osteomyelitis. Biomedicine and Pharmacotherapy, 2007, 61, 272-276.	2.5	9
148	Surgical debridement with muscle flap transposition and systemic teicoplanin therapy for infected hip arthroplasty. HIP International, 2010, 20, 255-257.	0.9	8
149	MEDical wards Invasive Candidiasis ALgorithms (MEDICAL):Consensus proposal for management. European Journal of Internal Medicine, 2016, 34, 45-53.	1.0	8
150	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	1.1	8
151	Specific dynamic of serum procalcitonin in critically ill patients affected by Gram-negative bacilli septic thrombophlebitis. Critical Care, 2018, 22, 178.	2.5	8
152	High Activity of N-Acetylcysteine in Combination with Beta-Lactams against Carbapenem-Resistant Klebsiella pneumoniae and Acinetobacter baumannii. Antibiotics, 2022, 11, 225.	1.5	8
153	Clinical and in vitro efficacy of colistin plus vancomycin and rifampin against colistin-resistant Acinetobacter baumannii causing ventilator-associated pneumonia. New Microbiologica, 2017, 40, 205-207.	0.1	8
154	Portal Hypertension Related to Schistosomiasis Treated With a Transjugular Intrahepatic Portosystemic Shunt. Journal of Clinical Gastroenterology, 2016, 50, 608-610.	1.1	7
155	Management of candidemia in patients withClostridium difficileinfection. Expert Review of Anti-Infective Therapy, 2016, 14, 679-685.	2.0	7
156	Candidaemia after heart valve replacement surgery: recurrence as prosthetic valve endocarditis is an expected over one-year complication. Clinical Microbiology and Infection, 2016, 22, 466-467.	2.8	7
157	A cost analysis of a broad-spectrum antibiotic therapy in the empirical treatment of health care-associated infections in cirrhotic patients. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 385-390.	0.7	7
158	What are the treatment options for resistant <i>Klebsiella pneumoniae</i> carbapenemase (KPC)-producing bacteria?. Expert Opinion on Pharmacotherapy, 2020, 21, 1781-1787.	0.9	7
159	Procalcitonin in daily clinical practice: an evergreen tool also during a pandemic. Internal and Emergency Medicine, 2021, 16, 541-543.	1.0	7
160	Reply to Di Paolo et al. Clinical Infectious Diseases, 2014, 58, 1789-1790.	2.9	6
161	Early identification of severe community-onset pneumonia in "frail elderly patient― Internal and Emergency Medicine, 2014, 9, 119-120.	1.0	6
162	Spontaneous bacterial peritonitis due to methicillin-resistant Staphylococcus aureus in a patient with cirrhosis: the potential role for daptomycin and review of the literature. Gastroenterology Insights, 2015, 7, 6127.	0.7	6

#	Article	IF	CITATIONS
163	The prophylaxis of infective endocarditis: a joint position study of the Italian Federation of Cardiologists and the Italian Society of Infectious and Tropical Diseases. Journal of Cardiovascular Medicine, 2010, 11, 419-425.	0.6	5
164	Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosis. Journal of Antimicrobial Chemotherapy, 2010, 65, 2266-2267.	1.3	5
165	Healthcare-Associated Pneumonia and Multidrug-Resistant Bacteria: Do We Have a Convincing Answer?. Clinical Infectious Diseases, 2014, 58, 1196-1197.	2.9	5
166	Role of oral nystatin prophylaxis in cardiac surgery with prolongedextracorporeal circulation. Mycoses, 2017, 60, 826-829.	1.8	5
167	Gram-negative septic thrombosis in critically ill patients: A retrospective case–control study. International Journal of Infectious Diseases, 2020, 94, 110-115.	1.5	5
168	Diagnostic stewardship based on patient profiles: differential approaches in acute versus chronic infectious syndromes. Expert Review of Anti-Infective Therapy, 2021, 19, 1373-1383.	2.0	5
169	Health Care–Associated Pneumonia: A New Clinical Entity. Archives of Internal Medicine, 2008, 168, 109.	4.3	4
170	Severe community onset healthcare-associated Clostridium difficile infection complicated by carbapenemase producing Klebsiella pneumoniae bloodstream infection. BMC Infectious Diseases, 2014, 14, 475.	1.3	4
171	Nursing home residence is associated with spread of Clostridium difficile ribotype 027 in central Italy. Journal of Hospital Infection, 2016, 94, 201-203.	1.4	4
172	Diagnostic and therapeutic appropriateness in bone and joint infections: results of a national survey. Journal of Chemotherapy, 2016, 28, 191-197.	0.7	4
173	Impact of continuous renal replacement therapy (CRRT) and other extracorporeal support techniques on procalcitonin guided antibiotic therapy in critically ill patients with septic shock. Clinical Chemistry and Laboratory Medicine, 2019, 57, e86-e87.	1.4	4
174	First report of spondylodiscitis caused by Bacillus circulans in an immunocompetent patient: Clinical case and review of the literature. IDCases, 2021, 23, e01058.	0.4	4
175	Prior Antibiotic Therapy and the Onset of Healthcare-Associated Infections Sustained by Multidrug-Resistant Klebsiella pneumoniae in Intensive Care Unit Patients: A Nested Case–Control Study. Antibiotics, 2021, 10, 302.	1.5	4
176	CURB-65 plus hypoalbuminemia: a new score system for prediction of the in-hospital mortality risk in patients with SARS-CoV-2 pneumonia. Infezioni in Medicina, 2021, 29, 408-415.	0.7	4
177	Fast and reliable diagnosis of XDR Acinetobacter baumannii meningitis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. New Microbiologica, 2018, 41, 77-79.	0.1	4
178	Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios. Expert Review of Anti-Infective Therapy, 2022, 20, 997-1004.	2.0	4
179	Clinical Experience of Anidulafungin for the Treatment of Patients with Documented Candidemia. Journal of Chemotherapy, 2010, 22, 397-401.	0.7	3
180	Carbapenem-resistant Klebsiella pneumoniae transmission associated toÂendoscopy. American Journal of Infection Control, 2013, 41, 849-850.	1.1	3

#	Article	IF	CITATIONS
181	Procalcitonin as guide to therapy in endovascular infections: caveat emptor!. Clinical Chemistry and Laboratory Medicine, 2019, 57, e52-e53.	1.4	3
182	Efficacy of Daptomycin-Containing Regimen for Treatment of Staphylococcal or Enterococcal Vertebral Osteomyelitis: A Prospective Clinical Experience. Antibiotics, 2020, 9, 889.	1.5	3
183	Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single-centre experience and review of the literature New Microbiologica, 2022, 45, 62-72.	0.1	3
184	Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections in Patients With Liver Cirrhosis. Journal of Clinical and Experimental Hepatology, 2022, 12, 1293-1300.	0.4	3
185	Topical nystatin prophylaxis: a likely viable measure for reducing impact of candidemia in neurosurgical patients with early tracheostomy intubation. Critical Care, 2013, 17, 414.	2.5	2
186	CAP and HCAP are different? An unresolved question. Thorax, 2014, 69, 676-677.	2.7	2
187	Healthcare-associated pneumonia: a never-ending story. Gastroenterology Insights, 2014, 6, 5387.	0.7	2
188	Updates in the epidemiology and management of candidemia and <i>Clostridioides difficile</i> coinfection. Expert Review of Anti-Infective Therapy, 2019, 17, 375-382.	2.0	2
189	Preliminary Attempt to Predict Risk of Invasive Pulmonary Aspergillosis in Patients with Influenza: Decision Trees May Help?. Antibiotics, 2020, 9, 644.	1.5	2
190	Vertebral osteomyelitis caused by vancomycin-resistant Enterococcus spp.: a case series. International Journal of Antimicrobial Agents, 2021, 58, 106432.	1.1	2
191	Monocyte absolute count as a preliminary tool to distinguish between SARS-CoV-2 and influenza A/B infections in patients requiring hospitalization. Infezioni in Medicina, 2020, 28, 534-538.	0.7	2
192	An outbreak sustained by ST15 Klebsiella pneumoniae carrying 16S rRNA methyltransferases and blaNDM: evaluation of the global dissemination of these resistance determinants. International Journal of Antimicrobial Agents, 2022, 60, 106615.	1.1	2
193	Successful Conservative Treatment of Descending Necrotizing Mediastinitis With Fistula Formation in the Hypopharynx. Infectious Diseases in Clinical Practice, 2005, 13, 36-38.	0.1	1
194	Role of aspirin in patients with septic shock: a complex and intriguing relationship. Intensive Care Medicine, 2016, 42, 1097-1097.	3.9	1
195	Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight mass spectrometry assay solves misidentification of rapidly growing mycobacteria. American Journal of Infection Control, 2016, 44, 614-616.	1.1	1
196	The Role of Combination Therapy in Critically Ill Patients With Methicillin-susceptible Staphylococcus aureus Bloodstream Infections: Does The Question Remain?. Clinical Infectious Diseases, 2020, 73, 167-168.	2.9	1
197	Successful conservative treatment of peripheral candidal thrombophlebitis: case report. Mycoses, 2011, 54, e653-e655.	1.8	0
198	Reply to: "The Possible Role of Anti-Methicillin-Resistant Staphylococcus Aureus Antimicrobial Agents in Spontaneous Bacterial Peritonitisâ€. Gastroenterology Insights, 2015, 7, 6356.	0.7	0

#	Article	IF	CITATIONS
199	Betaâ€blockers in patients with cirrhosis and infections: don't blame too soon!. Liver International, 2015, 35, 1778-1779.	1.9	O
200	The current role of glycopeptides in the treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts. Journal of Chemotherapy, 2018, 30, 157-171.	0.7	0
201	Early antibiotic treatment in emergency department: the critical balance. Internal and Emergency Medicine, 2021, 16, 1743-1745.	1.0	O